Advertisement

AesRx LLC, a sickle cell disease-focused biotech firm in Newton, is working with the National Institutes of Health to bring its treatment, Aes-103, to clinical trials.

Designated an orphan drug by the U.S. Food and Drug Administration, Aes-103 was developed for the purpose of lowering the instances of blood cell sickling, a genetic blood defect that causes misshaping of red blood cells. Patients infected with sickle cell disease may experience chronic pain, chronic hemolytic anemia, acute chest syndrome and damage to tissue and organs.

SOURCE

Advertisement
Advertisement